Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Randomized (1:1) Clinical Trial to Evaluate Switching From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE Study).

NCT03493568 is registered in ClinicalTrials.gov with IRCCS San Raffaele as lead sponsor.

NCT NCT03493568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03493568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Randomized (1:1) Clinical Trial to Evaluate Switching From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE Study).
Lead sponsor
IRCCS San Raffaele
Phase
Phase 3
Overall status
Terminated
Start date
February 6, 2017
Completion date
July 31, 2020
Enrollment
100 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection